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OVEREXPRESSION AND PARTIAL PURIFICATION OF RECOMBINANT
HUMAN SERINE HYDROXYMETHYLTRANSFERASE:
A POTENTIAL ANTICANCER TARGET

I. INTRODUCTION
Serine hydroxymethyltransferase (SHMT) (E.C. 2.1.2.1) is a ubiquitous enzyme
that plays a central role in the metabolism of growing tissues undergoing a high rate of DNA
synthesis. This pyridoxal-5’-phosphate (PLP)-dependent enzyme provides precursors and
cofactors for nucleotide biosynthesis by catalyzing the reversible interconversion of serine
and tetrahydrofolate with glycine and N5, N10-methylenetetrahydrofolate. This aldolase
reaction is unusual for a PLP-dependent enzyme and has been studied.1 In addition,
X-ray crystallographic studies on SHMT from various sources, including humans, have
provided useful structural information.2 The human cytosolic form of SHMT (483 AA) is
a 53,083 Da homotetramer with a calculated pI of 7.61. Despite the structural knowledge
present, there is still some question regarding the mechanism for this conversion.1 One
possibility is a retroaldol mechanism with free formaldehyde as an intermediate and that is

Figure 1. Proposed mechanism for the interconversion of serine and tetrahydrofolate with glycine and
N5,N10-methylenetetrahydrofolate.

subsequently attacked by tetrahydrofolate.1 Alternatively, the N5 of tetrahydrofolate makes
a nucleophillic attack on serine C3 leading to the breakage of the C3-C2-bond of serine
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rather that the C3-hydroxyl bond (Figure 1).1 Even though the first mechanism requires an
active site base that is not apparent in the active site, it is not possible to definitively rule
out this mechanism.

Figure 2. The thymidylate synthase cycle showing the transfer of a one carbon group from serine to
N5, N10-methylenetetrahydrofolate by SHMT.

In the thymidylate synthase cycle the N5, N10-methylenetetrahydrofolate produced
by SHMT is directly involved in pyrimidine biosynthesis by donating a methyl group
used for methylating dUMP to dTMP (Figure 2). In addition, the glycine produced in the
SHMT catalyzed reaction can serve as a precursor in purine biosynthesis by providing
two carbons and a nitrogen to the purine ring. With both of the reaction products involved
in nucleotide biosynthesis, it is not surprising that SHMT activity was shown to be upregulated in various cancer cell types.3,4 Furthermore, the inhibition of SHMT in myeloma
cells in culture results in dose-dependent inhibition of cellular growth provides support
that SHMT is a suitable target for anticancer pharmaceuticals.5 The other two enzymes
in the thymidylate synthase cycle, thymidylate synthase (TS) and dihydrofolate reductase
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(DHFR), are anticancer targets. This is important because drugs that target TS and DHFR
are susceptible to drug resistance, and they are toxic themselves.6

Figure 3. The chemical structure for triazine antifolate (NCS 127755).

Previous work on the classic inhibitors of DHFR viz. methatrexate and its
structural analogs failed to inhibit SHMT activity significantly.7

Triazine antifolate

(NCS 127755) (Figure 3) was the only compound with reasonable inhibition of SHMT.5
Formyltetrahydrofolate derivatives were found to be slow tight binding inhibitors of SHMT.8
Serine analogs using putative mechanism based inactivators as possible chemotherapeutic
agents have also previously been explored, but were not promising.7

d-cycloserine

(DCS)

inhibited SHMT, and it was suggested as a possible chemotherapeutic agent.6,9,10 However,
DCS is a very general PLP dependent enzyme inhibitor and would also inhibit other PLP
dependent enzymes. Structurally related compounds to DCS, such as o-amino-d-serine
(OADS) inhibited SHMT with Ki values nearly 500 × less than Km values of serine.11
4-chloro-l-threonine inhibited SHMT, but it was suggested that β-trifluoroallothreonine
and β-trifluorothreonine might act suicide substrates and may be more specific and better
inhibitors of SHMT.12
Mimosine is a plant amino acid (Figure 4) that was found to effectively inhibit
SHMT, possibly both the mitochondrial and the cytosolic forms of SHMT, resulting in
an inhibition of DNA replication in mammalian cells.13 However, more work is required
to test its effectiveness as a possible drug. Thiosemicarbazide (TSC) was shown to be a
slow but tight binding inhibitor to SHMT.14 Kinetic studies with substituted derivatives of
TSC revealed that the presence of a H2NHN—C=S group in the inhibitor is important in
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Figure 4. Chemical structure of mimosine.

the interaction. Based on this finding, it was suggested that serine and glycine derivatives
containing H2NHN—C=S could be highly potent and specific inhibitors of SHMT with
promise as chemotherapeutic agents.15
Although there are some potential candidates, the goal of this research is to perform
enzymatic studies on hSHMT in order to identify and screen possible inhibitors that may
be used as chemotherapeutics for the treatment of cancer. Pure hSHMT is required for
performing the enzymatic studies for kinetically characterizing the physiological relevant
aldolase reaction catalyzed by SHMT. The cDNA clone coding for human SHMT was
heterologously overexpressed in Escherichia coli (BL21 strain) and the recombinant protein
was partially purified. Attempts to affinity-purify hSHMT using a Ni+2 chelating column
were unsuccessful and hSHMT was only partially purified by selective salt precipitations
followed by both gel-filtration and anion-exchange chromatography. The cDNA clone
was used as a template to amplify the gene coding for hSHMT, and was subcloned into
a pET151/D-TOPO (Invitrogen) plasmid. This paper will focus on the purification of
recombinant hSHMT, and the cloning process.
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II. EXPERIMENTAL METHODS

Materials
l-(+)-arabinose

was purchased from Sigma. All other commercial chemicals were

purchased from Fisher. PfuTurbo DNA polymerase was purchased from Stratagene. The
Champion pET151/D-TOPO vector was purchased from Invitrogen. Taq DNA polymerase,
HindIII, and NdeI were purchased from New England BioLabs (NEB). KpnI and BamHI
were purchased from Fisher Scientific. SacI was purchased from Promega.
Overexpression of Recombinant hSHMT
Cells were scraped from a frozen stock of Escherichia coli BL21 and inoculated into
5 mL of Luria-Bertani (LB) medium with ampicillin (Ap) and chloramphenicol (Cm) to a
final concentration of 50 μg mL-1 and 34 μg mL-1, respectively, and grown with shaking at
37 °C overnight. The next morning, the entire overnight culture was aseptically transferred
into 500 mL of sterile LB medium containing Ap and Cm to a final concentration of
50 μg mL-1 and 34 μg mL-1 respectively, and grown with shaking at 37 °C. At an optical
density (OD) at 600 nm of 0.6, l-(+)-arabinose was added to a final concentration of 1%
(w/v) to induce the overexpression of the plasmid-encoded gene product (SHMT). After
five hours, the culture was removed and the cells were harvested at 4 °C by centrifugation
for 15 minutes at 1,571 × g. The cell pellet was either stored at –70 °C, or resuspended in
20 mM Tris-HCl buffer (pH 7.5) and then stored at –70 °C.
Cell Lysis
After thawing the cells in ice, cold 20 mM Tris-HCl buffer (pH 7.5) was added to the
cell pellet and vortexed until completely resuspended. Cells that were resuspended prior
to storage at –70 °C were also vortexed to ensure that they were completely suspended.
After the cells were completely suspended, lysozyme was added to a final concentration of
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0.5 mg mL-1 and incubated with shaking for 20 to 30 minutes on ice. The cell suspension
was disrupted in an ice-water bath with a Ultrasonic Processor XL (Heat Systems) at an
intensity of 2.5, using 80 1.5 second treatments with a 10 second pause between each
treatment. The cellular debris was removed at 4 °C by centrifugation for 20 minutes at
12,096 × g.
Purification of hSHMT by Anion-Exchange FPLC
Ammonium sulfate was slowly added to the lysate (supernatant after cell lysis) to
30% saturation at 0 °C and stirred for 10 minutes. The solution was equally distributed into
1.5 mL tubes and centrifuged at 4 °C for 15 minutes at 16,000 × g. The resulting supernatant
was subjected to ammonium sulfate precipitation from 30 to 70 % saturation at 0 °C and
stirred for 10 minutes. The precipitate was collected after centrifuging at 4 °C for 15
minutes at 16,000 × g and was resuspended in a minimal amount of 20 mM Tris-HCl buffer
(pH 7.5). The resuspended protein sample was applied onto a Bio-Scale Mini Bio-Gel P-6
Desalting Cartridge (BioRad) and eluted with ice-cold 20 mM Tris-HCl buffer (pH 7.9).
The fractions were analyzed with an OceanOptics USB 2000 spectrophotometer at 280 nm.
The fractions with the highest absorbance at 280 nm were pooled and concentrated to about
one milliliter using a 50,000 MWCO (Vivaspin) concentrator centrifuged at 2,000 × g
(4 °C). The concentrated protein sample was further purified by anion-exchange on a UNO
Sphere Q (Bio Rad) column connected to BioLogic DuoFlow FPLC system (Bio Rad) at
4 °C. The column was first equilibrated with 20 mM Tris-HCl buffer (pH 7.9), the 1 mL
sample was injected onto the column, and the column was washed with 5 column volumes
of the same buffer. The column eluted with a linear gradient of 0 M to 1 M NaCl in 20 mM
Tris-HCl buffer (pH 7.9) over 10 column volumes, followed by an isocratic flow of 1 M
NaCl in 20 mM Tris-HCl buffer (pH 7.9) for 5 column volumes. The absorbance at 280
nm was measured for all the fractions, and select fractions were analyzed by SDS-PAGE.
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Enzyme Assay
The relative quantity of SHMT was estimated spectrophotometerically at room
temperature by measuring the disappearance of NADH that accompanies the reduction
of acetaldehyde formed from the SHMT catalyzed aldol cleavage of l-allo-threonine to
glycine (Figure 5). The assay was prepared by incubating a protein sample with 1 mM

Figure 5. The reactions involved in the assay. l-allo-threonine is reacted overnight, and the activity is
measured by the fast reaction of acetaldehyde to ethanol by ADH.
l-allo-threonine

and 20 μM PLP in 50 mM phosphate buffer (pH 7.5) overnight. After the

addition of 204 μM NADH, the initial absorbance at 340 nm was recorded, and the final
the absorbance at 340 nm after incubating with 30,000 U of alcohol dehydrogenase (ADH)
for 4 minutes. The relative quantity of SHMT was calculated by dividing the change in
absorbance at 340 nm by the total amount of protein in that sample, which was estimated
with a spectrophotometer at 280 nm using an extinction coefficient of 1.
Ni+2-NTA Affinity-Chromatography
Affinity purification of SHMT from the lysate in a single step was originally
attempted using Ni+2-NTA His-Bind Superflow (Novagen) resin (0.5 mL bed volume) in
a 5 mL polypropylene column. Lysate that was prepared in equilibration buffer (20 mM
Tris-HCl, 10 mM Imidazole, 100 mM NaCl, pH 7.9) was loaded onto the column and the
column was washed with 10 column volumes of ice-cold equilibration buffer. The column
was eluted with 10 column volumes of ice-cold elution buffer (20 mM Tris-HCl, 500 mM
Imidazole, pH 7.9) while collecting 1 mL fractions. The fractions were analyzed with an
OceanOptics USB 2000 spectrophotometer at 280 nm and by SDS-PAGE.
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Affinity purification of SHMT was then attempted using a Ni-Mac Cartridge
(Novagen). Lysate that was prepared in MAC bind buffer (300 mM NaCl, 50 mM sodium
phosphate, 10 mM imidazole, pH 8.0) was loaded onto the column, washed with 6 column
volumes of ice-cold MAC wash buffer (300 mM NaCl, 50 mM sodium phosphate, 20 mM
imidazole, pH 8.0), and eluted with 6 column volumes of ice-cold MAC elute buffer
(300 mM NaCl, 50 mM sodium phosphate, 250 mM imidazole, pH 8.0). The fractions
having the highest absorbance at 280 nm were analyzed by SDS-PAGE and enzyme assay.
Subcloning of hSHMT into pET151/D-TOPO
SHMT cDNA was amplified by PCR using the following primers: (forward)
5′ CAC CAT GAC GAT GCC AGT CAA 3′ and 5′ GTG GTG AAG CTT TTA GAA
GTC AGG CAG GCC AG 3′ (reverse). The reaction was carried out using the following
concentrations: 2.5 U of PfuTurbo DNA Polymerase (Stratagene), 1.0 × Pfu reaction
buffer, 1.0 mM dNTPs, 0.5 µM of forward primer, 0.5 µM of reverse primer, and 90 ng of
plasmid DNA. The following cycling parameters were used: initial denature at 95 °C for
5 minutes; 95 °C for 60 seconds, 58–62 °C for 60 seconds, 72 °C for 60–90 seconds for
30 cycles; final extension at 72 °C for 10 minutes; hold at 4 °C. The PCR product was gel
purified from a 1% agarose gel in 1 × TAE buffer by using a QIAprep kit.
Subcloning of hSHMT cDNA into a pET151D-TOPO (Invitrogen) vector was
performed by adding the following into a sterile PCR tube: 5 ng of gel-purified PCR
product, 1 μL of Champion pET151/D-TOPO (Invitrogen) vector, 2.75 μL of salt solution,
and 1 μL of sterile water. This was gently mixed and incubated at room temperature for
10 minutes before transferring 3 μL to a vial of One Shot TOP10 Chemically Competent
E. coli cells and incubating on ice for 10 minutes. The cells were heat-shocked for 30
seconds at 42 °C and immediately placed in ice before 250 μL of sterile room temperature
LB medium was added. The cells were incubated while shaking at 37 °C for 1 hour before
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transferring 200 μL and 100 μL onto individual pre-warmed LB/Ap plates. The cell culture
was spread evenly, and incubated agar-side-up at 37 °C for 24 hours.
Colony Screening
Plasmid DNA was extracted from colonies, and was analyzed by using a
combination of different restriction enzymes. All restrictions were performed overnight,
using the recommended buffers for double digestions. The enzyme combinations used to
cut once in the vector and once in the insert were HindIII and NdeI, KpnI and SacI, NdeI
and BamHI, KpnI and SacI. The plasmid was also restricted at the sites flanking the insert
with NdeI and SacI.
Colonies were also screened by PCR amplification of the insert using the following
primers: (forward) 5′ CAC CAT GAC GAT GCC AGT CAA 3′ and 5′ GTG GTG AAG
CTT TTA GAA GTC AGG CAG GCC AG 3′ (reverse). The reaction was carried out
using the following concentrations: 1.25–5 U of Taq DNA Polymerase, 1.0 × of standard
Taq reaction buffer (NEB), 200 µM–1000 mM dNTPs, 1–1.5 µM of forward primer,
1–1.5 µM of reverse primer, and 90 ng of plasmid DNA. The following cycling parameters
were used: initial denature at 94 °C for 3 minutes; 94 °C for 45 seconds, 55–62 °C for 30
seconds, 72 °C for 90 seconds for 30 cycles; final extension at 72 °C for 10 minutes; hold
at 4 °C. The following parameters suggested by the manufacturer were also used: initial
denature at 95 °C for 30 seconds; 95 °C for 30 seconds, 60 °C for 30 seconds, 68 °C for
90 seconds for 30 cycles; final extension at 68 °C for 10 minutes; hold at 4 °C. The PCR
products were analyzed by electrophoresis using a 1% agarose gel in 1 × TAE buffer.
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III. RESULTS

Purification of hSHMT by Anion-exchange FPLC
Crude lysate from E. coli was purified by selective ammonium sulfate fractionation
at 0–30% and 30–70% saturation, the protein sample was desalted and concentrated to
1 mL for purification by anion-exchange FPLC. The absorbance at 280 nm was measured
for each fraction and an elution profile was constructed (Figure 6). The first peak from
fraction 1 to fraction 6 is the flow-through peak that contains unbound proteins; the second
and third peaks are not resolved. The coupled assay was used to identify active fractions
containing active hSHMT from these elution peaks. The bulk of the hSHMT was eluted
from the column from 20% to 76% of elution buffer, and was found in F24–F35. hSHMT
was detected in fractions 4, 5, 9 during the isocratic flow of 20 mM Tris-HCl buffer (pH 7.9),

Figure 6. Protein elution pattern (black line) and elution buffer percentage (red line) overlaid with
hSHMT activity (grey bar) Protein elution pattern was determined by measuring the absorbance at 280
nm for each fraction. The hSHMT activity was measured by a coupled assay with l-allo-threonine and
ADH.
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Figure 7. Fractions were analyzed by SDS-PAGE using a 5% stacking and a 12% resolving
polyacrylamide gel at 200–220 V and visualized by coomassie blue staining. All samples were reduced
with DTT.

with fractions 4 and 5 containing large amounts of hSHMT. Traces of hSHMT were also
detected in fractions 41, 44, and 47 during the isocratic flow of 100% elution buffer. In
the SDS-PAGE analysis of fractions 24–29 and fraction 3 (Figure 7), all the fractions were
found to contain multiple bands; all of these fractions also contained a 53 kDa band that
corresponded to hSHMT. The anion-exchange FPLC resulted in the partial purification of
hSHMT.
Ni+2-NTA affinity-chromatography
The Ni+2-NTA affinity-chromatography of hSHMT was performed by applying
crude lysate from E. coli directly to the column, the unbound (flow-through), washes
1–3, and eluted fractions 1–3 were analyzed by SDS-PAGE. The results (Figure 8) show
multiple bands in each of the eluted fractions. The Ni+2-NTA affinity-chromatography did
not purify the protein. The highest MW band was 53 kDa, and it was visible in the unbound
protein lane, elute 1, and elute 2. This is important because the 53 kDa band corresponds
to hSHMT without a polyhistidine affinity tag and a large amount of this protein did not
bind to the column. The enzyme assay was used to analyze wash 1, and eluted fractions
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Figure 8. Fractions from the Ni+2-NTA affinity-purrification of hSHMT were subjected to SDS-PAGE
in a 5% stacking and 12% resolving polyacrylamide gel at 170–220 V and visualized with coomassie
blue staining. All samples were adjusted to contain equal protein concentrations, and reduced with DTT.

1–3. The results identified elution fraction 1 and wash 1 to contain active hSHMT; elution
fraction 1 to contain more SHMT than wash 1 (results not shown).
Subcloning of hSHMT cDNA into pET151/D-TOPO
The PCR amplification of hSHMT cDNA resulted in two bands when analyzed
by electrophoresis in a 1% agarose gel (Figure 9). One band was approximately 1,500 bp
and the other band was approximately 1,000 bp. The 1,500 bp band was gel purified using
a QIAprep kit and no band was visible when 5 mL of 4.0 ng µL-1 gel-purified DNA was
analyzed by agarose gel electrophoresis (results not shown). Nevertheless, the gel-purified
DNA fragment was subcloned into a pET151/D-TOPO vector and 100 μL of transformed
cells were plated. This resulted in 14 isolated colonies on plate 1, and 8 isolated colonies
on plate 2.
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Figure 9. PCR amplification of hSHMT cDNA with PfuTurbo DNA polymerase was subjected to
electrophoresis in a 1% agarose gel containing EtBr with 1 × TAE buffer at 90 V and visualized under
UV light.

Colony Screening
Plasmid DNA was extracted from 4 colonies on plate 1 (P1C1, P1C2, P1C5, P1C7),
and from 2 colonies on plate 2 (P2CA, P2CI). Plasmid DNA labeled P1C2, P1C5, P1C7,
P2C2 was restricted with NdeI and HindIII and analyzed by electrophoresis on a 1%
agarose gel (Figure 10). The fragment sizes for P1C2, P1C5, P1C7, P2C2 were calculated
to be 6445 bp, 6956 bp, 6801 bp, 5313 bp, respectively.
In figure 11, the KpnI and SacI restriction of P1C1, P1C7, P2CA, P2CI resulted
in single fragments, and the calculated sizes were 5982 bp, 6090 bp, 6145 bp, 5466 bp,
respectively. P1C2 was restricted with NdeI and SacI, NdeI and BamHI, KpnI and SacI and
the fragment size were calculated to be 5467 bp, 5667 bp, 5982 bp, respectively.
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Figure 10. Plasmid DNA was restricted (cut) with NdeI and HindIII and subjected to electrophoresis
in a 1% agarose gel with 1 × TAE buffer at 90 V. The DNA was visualized with EtBr staining under
UV light.

Figure 11. Plasmid DNA was restricted (cut) with either KpnI and SacI, NdeI and SacI, NdeI and
BamHI, or NdeI and HindIII and subjected to electrophoresis in a 1% agarose gel with 1 × TAE buffer
at 90 V. The DNA was visualized with EtBr staining under UV light.
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PCR Analysis of Isolated Clones
Plasmid DNA was PCR amplified using hSHMT cDNA sequence specific primers
to help screen colonies for the presence of hSHMT subcloned into a pET151/D-TOPO
vector. The PCR products were analyzed by electrophoresis in a 1% agarose gel. The
results in figure 12 show that the sequence specific primers did not amplify the hSHMT
cDNA from P1C1. The control PCR amplification of circular pET151/D-TOPO resulted
in a single band that was approximately 380 bp. In figure 13 the PCR amplification of
plasmid DNA P1C1, P2CI, P1C7, P2CA resulted in 3 bands with fragment lengths around
9,000 bp, 3,500 bp, and 1,900 bp.

Figure 12. PCR amplification of plasmid DNA P1C1 and the negative control (pET151/D-TOPO
plasmid) was performed using 5 U of Taq DNA polymerase, 3.0 mM MgCl2, and with a primer annealing
temperature of 55 °C. The samples were subjected to electorphoresis in a 1% agarose gel containing
EtBr in 1 × TAE buffer at 90 V and visualized under UV light.

Figure 13. PCR amplification was performed using 1.25 U of Taq DNA polymerase, 2.0 mM MgCl2,
and with a primer annealing temperature of 60 °C. The samples were subjected to electorphoresis in a
1% agarose gel containing EtBr in 1 × TAE buffer at 90 V and visualized under UV light.
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IV. DISCUSSION and CONCLUSION
The main goal for this project was to obtain pure human serine
hydroxymethyltransferase with the ultimate goal to isolate possible inhibitors of SHMT.
Human SHMT was overexpressed in E. coli and partially purified by selective ammonium
sulfate fractionation and anion-exchange fast protein liquid chromatography.
It was expected that the purification of hSHMT from crude extract (lysate) by
selective ammonium sulfate fractionation at 0–30% and 30–70% saturation, followed by
subsequent anion-exchange fast protein liquid chromatography would result in significant
purification of the protein as evidenced by a dominant band at 53 kDa when analyzed
by SDS-PAGE. The FPLC elution profile was expected to have all of the hSHMT in a
single well-resolved peak. The results obtained from anion-exchange FPLC and from the
coupled assay with l-allo-threonine (Figure 6) did not show this. Instead, a large amount
of hSHMT was found in the flow-through peak (F3, F4), and the bulk of the hSHMT was
not detected in a single well-resolved peak; hSHMT was also detected in fractions 9, 41,
44, and 47. The SDS-PAGE results (Figure 7) showed multiple bands in addition to a 53
kDa band in F3, and F24–29. The detection of hSHMT in the flow-through peak is most
likely the result of exceeding the binding capacity of the column. It is believed that this
was caused by the binding of sheered nucleic acid fragments, which is supported by the
strong absorbance at 260 nm relative to 280 nm in these fractions. The multiple bands
observed in the SDS-PAGE analysis were the result of poor separation of hSHMT from
E. coli proteins. It is unknown if the detection of hSHMT in F41, F44, and F47 by the
coupled assay were false positives since these fractions were not analyzed by SDS-PAGE.
However, fraction 9 is believed to be a false positive caused by contamination because it
does not contain any protein, as indicated by a lack of absorbance at 280 nm. Based on
these results, it was determined that our methods of overexpressing and purifying hSHMT
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by selective ammonium sulfate fractionation and anion-exchange FPLC were unsuccessful
in accomplishing our goal to obtain pure hSHMT.
After the unsuccessful purification of hSHMT by anion-exchange FPLC, the
purification of hSHMT in a single step using Ni+2-NTA affinity chromatography was
evaluated. It was expected that the purification of hSHMT from E. coli lysate would
result in a single band with a MW greater than 53 kDa when analyzed by SDS-PAGE.
However, the obtained results were not as expected. Instead, multiple bands were observed
in addition to a 53 kDa band in the eluted fraction as well as the unbound fraction. These
multiple bands were the result of eluting the column before all non-specific bound proteins
had been washed out of the column. The first wash and the three eluted fractions were
analyzed with the coupled assay, and the results determined that wash 1 and elution 1
both contained active hSHMT (wash 2 and wash 3 were not analyzed). Taken together,
these results support that hSHMT was not expressed as a fusion protein containing a
polyhistidine affinity tag. Fusion proteins that contain polyhistidine affinity tags such as
His6 or His10 will commonly have additional amino acids in between the protein and the
polyhistidine tag to act as a spacer as well as offer a cleavage site for removing the affinity
tag after purification. Therefore, hSHMT containing a polyhistidine affinity tag would
have a greater MW than native hSHMT without any affinity tag. The largest MW band in
elute 1 was approximately 53 kDa, which indicates that it is native hSHMT (un-tagged).
The Ni+2-NTA affinity-purification trials concluded that hSHMT was not expressed
as a fusion protein containing a polyhistidine tag. This led to the decision to PCR amplify
hSHMT cDNA from the arabinose-induced plasmid and subclone it into a pET151/D-TOPO
(Invitrogen) vector for better over-expression and easier purification by Ni+2-NTA affinity
chromatography. Other researchers have reported that the overexpression and purification
of human recombinant SHMT by Ni+2-NTA affinity chromatography yielded up to 15 mg
of pure hSHMT from 1 L of bacterial culture.16
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In the subcloning process of hSHMT, the PCR amplification of hSHMT cDNA
resulted in two bands; one that was approximately 1,500 bp and the other was approximately
1,000 bp. Different parameters were adjusted in order to optimize the PCR amplification
that would result in a single band of approximately 1,500 bp. The primer annealing
temperature was increased, the primer extension time was increased from 60 seconds to 90
seconds, and primer concentration was decreased. However, optimal PCR amplification
conditions were not achieved by these adjustments, and the desired 1,500 bp band was
gel-purified.
Colonies were screened for hSHMT cDNA by both restriction analysis and PCR
amplification of isolated plasmid DNA. A single band was observed from the restriction
analysis of all the colonies, which is not expected from the successful subcloning of
hSHMT cDNA into pET151/D-TOPO. Fragment sizes of 5,760 bp and 1,554 bp, 5,980 bp
and 1,244 bp, 5,652 bp and 1,572 bp, 6,295 bp and 929 bp were expected for the restriction
of plasmid DNA with NdeI and HindIII, KpnI and SacI, NdeI and SacI, NdeI and BamHI.
For the colony screening by PCR amplification, a discrete band of 1,464 bp was expected
from colonies containing hSHMT cDNA. The results were not as expected; a 1,464 bp
band was not observed for any of the analyzed colonies. Based on the results from the
restriction analysis and PCR amplification of plasmid DNA isolated from transformed
colonies, it can be concluded that the subcloning of hSHMT cDNA into pET151/D-TOPO
was unsuccessful.
One possible explanation for this is that the pET151/D-TOPO vector had self ligated.
The other possibility is that the PCR product was degraded resulting in a smaller fragment
that was successfully ligated into the vector. The restriction of plasmid DNA obtained
from P2CI in figures 10 and 11 show a significantly smaller fragment compared the rest
of the colonies. This supports the possibility of degradation although the mechanism by
which such degradation occurred is unclear.
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In recent literature, zebrafish cytosolic serine hydroxymethyltransferase (zSHMT-1)
was over-expressed in E. coli and successfully purified 14.8 fold to 95% purity.17 The use
of CM-Sephadex greatly simplified and significantly increased the efficiency of zSHMT-1
purification because most E. coli proteins, including E. coli SHMT, were unable to bind
to cation exchange resins.17 They were able to remove the bulk of E. coli proteins to
achieve a 13.4 fold purification with 90% purity.17 Previous work to purify SHMT from
monkey liver also uses similar techniques to those used to purify zSHMT-1.17,18 The
purification steps for isolating SHMT from monkey liver involved ammonium sulfate
precipitation (25–50% saturation), CM-Sephadex ion-exchange chromatography, Ultrogel
AcA-34 gel chromatography, and the final step was either Blue Sepharose CL-6B affinity
chromatography to achieve a degree of purification of 183, or Folate-AH-Sepharose 4B
which gave a degree of purification of 189.17 Our results are not comparable to these
results that have been reported.
In this experiment, the coupled assay allowed us to detect active hSHMT throughout
the purification steps by monitoring the decrease in absorbance at 340 nm. However this
assay method was limited to the detection of active hSHMT only. Furthermore, the current
control (DI water) does not account for background activity caused by any E. coli enzymes.
One of the difficulties in this experiment was determining the presence of hSHMT by SDSPAGE analysis since the majority of the proteins present in the all the fractions were E. coli
proteins. In addition, the lack of a comparison of induced vs. un-induced E. coli lysate
made it difficult to determine if the 53 kDa band was hSHMT or an E. coli protein.
The detection of hSHMT on a SDS-PAGE gel can be improved by performing a
western blot using a specific antibody against hSHMT. This would also be able to detect
inactive hSHMT, which is not possible with our current coupled assay. The enzyme assay
could be improved by using the lysate from un-induced E. coli as a control. The use of
cation-exchange chromatography (cation-exchange FPLC) may result in better purification
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of hSHMT from E. coli proteins. In addition, the implementation of similar purification
methods described, such as size-exclusion or affinity chromatography can be used to
further purify hSHMT after anion-exchange FPLC.
In this project, hSHMT was overexpressed in E. coli and partially purified by
selective ammonium sulfate fractionation followed by anion-exchange fast protein liquid
chromatography. The active fractions were identified with the coupled assay using
l-allo-threonine

and ADH. The Ni+2-NTA affinity purification trials concluded that

hSHMT was not expressed as a fusion protein containing a polyhistidine affinity tag. The
gene encoding for human SHMT was then cloned into a pET151/D-TOPO (Invitrogen)
plasmid for better purification. A fraction of transformed colonies were screened for the
cloned gene by PCR amplification and restriction enzyme digestion of isolated plasmid
DNA. None of the colonies screened were found to contain the full-length hSHMT gene.
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